Cytotoxic responses to BLV tax oncoprotein do not prevent leukemogenesis in sheep

Leukemia Research

Volumn 34, Issue 12, 2010, Pages 1663-1669

  Van den Broeke, Anne ^a   Oumouna, Mustapha ^b,c   Beskorwayne, Terry ^b   Szynal, Maud ^a   Cleuter, Yvette ^a   Babiuk, Shawn ^b,d   Bagnis, Claude ^e   Martiat, Philippe ^a   Burny, Arsene ^a   Griebel, Philip ^b  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c UNIVERSITY OF BLIDA   (Algeria)

^d CANADIAN FOOD INSPECTION AGENCY   (Canada)

^e ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

B cell leukemia; BLV; Cytotoxic responses; HTLV 1; Leukemogenesis; Ovine model; Tax

Indexed keywords

DNA VACCINE; PROVIRUS PROTEIN; TAX PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LEUKEMIA; BOVINE LEUKEMIA VIRUS; CONTROLLED STUDY; DISEASE COURSE; DNA IMMUNIZATION; DRUG CYTOTOXICITY; FEMALE; LEUKEMOGENESIS; LYMPHOPROLIFERATIVE DISEASE; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; RETROVIRUS INFECTION; SHEEP; VIRUS LOAD;

EID: 78149357118     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.06.003     Document Type: Article

References (43)

1. Jeang K.T., Giam C.Z., Majone F., Aboud M. Life, death, and tax: role of HTLV-I oncoprotein in genetic instability and cellular transformation. J Biol Chem 2004, 279:31991-31994.
2. Yoshida M. Discovery of HTLV-1, the first human retrovirus, its unique regulatory mechanisms, and insights into pathogenesis. Oncogene 2005, 24:5931-5937.
3. Matsuoka M., Jeang K.T. Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007, 7:270-280.
4. Marriott S.J., Lemoine F.J., Jeang K.T. Damaged DNA and miscounted chromosomes: human T cell leukemia virus type I tax oncoprotein and genetic lesions in transformed cells. J Biomed Sci 2002, 9:292-298.
5. Willems L., Heremans H., Chen G., Portetelle D., Billiau A., Burny A., et al. Cooperation between bovine leukaemia virus transactivator protein and Ha-ras oncogene product in cellular transformation. EMBO J 1990, 9:1577-1581.
6. Willems L., Burny A., Collete D., Dangoisse O., Dequiedt F., Gatot J.S., et al. Genetic determinants of bovine leukemia virus pathogenesis. AIDS Res Hum Retroviruses 2000, 16:1787-1795.
7. Szynal M., Cleuter Y., Beskorwayne T., Bagnis C., Van L.C., Kerkhofs P., et al. Disruption of B-cell homeostatic control mediated by the BLV-Tax oncoprotein: association with the upregulation of Bcl-2 and signaling through NF-kappaB. Oncogene 2003, 22:4531-4542.
8. Klener P., Szynal M., Cleuter Y., Merimi M., Duvillier H., Lallemand F., et al. Insights into gene expression changes impacting B-cell transformation: cross-species microarray analysis of bovine leukemia virus tax-responsive genes in ovine B cells. J Virol 2006, 80:1922-1938.
9. Burny A., Cleuter Y., Kettmann R., Mammerickx M., Marbaix G., Portetelle D., et al. Bovine leukaemia: facts and hypotheses derived from the study of an infectious cancer. Cancer Surv 1987, 6:139-159.
10. Schwartz I., Levy D. Pathobiology of bovine leukemia virus. Vet Res 1994, 25:521-536.
11. Yoshida M., Miyoshi I., Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982, 79:2031-2035.
12. Hanon E., Hall S., Taylor G.P., Saito M., Davis R., Tanaka Y., et al. Abundant tax protein expression in CD4+ T cells infected with human T-cell lymphotropic virus type I (HTLV-I) is prevented by cytotoxic T lymphocytes. Blood 2000, 95:1386-1392.
13. Bangham C.R., Osame M. Cellular immune response to HTLV-1. Oncogene 2005, 24:6035-6046.
14. Bangham C.R., Meekings K., Toulza F., Nejmeddine M., Majorovits E., Asquith B., et al. The immune control of HTLV-1 infection: selection forces and dynamics. Front Biosci 2009, 14:2889-2903.
15. Jacobson S. Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J Infect Dis 2002, 186(Suppl 2):S187-S192.
16. Goon P.K., Biancardi A., Fast N., Igakura T., Hanon E., Mosley A.J., et al. Human T cell lymphotropic virus (HTLV) type-1-specific CD8+ T cells: frequency and immunodominance hierarchy. J Infect Dis 2004, 189:2294-2298.
17. Gillet N., Florins A., Boxus M., Burteau C., Nigro A., Vandermeers F., et al. Mechanisms of leukemogenesis induced by bovine leukemia virus: prospects for novel anti-retroviral therapies in human. Retrovirology 2007, 4:18.
18. Merimi M., Ozkan Y., Cleuter Y., Griebel P., Burny A., Martiat P., et al. Epigenetics and leukemia: unraveling oncogenic processes in the BLV ovine model. Front Biosci 2009, S1:154-163.
19. Mammerickx M., Palm R., Portetelle D., Burny A. Experimental transmission of enzootic bovine leukosis to sheep: latency period of the tumoral disease. Leukemia 1988, 2:103-107.
20. Nagai M., Osame M. Human T-cell lymphotropic virus type I and neurological diseases. J Neurovirol 2003, 9:228-235.
21. Ward W.H., Dimmock C.K., Eaves F.W. T lymphocyte responses of sheep to bovine leukaemia virus infection. Immunol Cell Biol 1992, 70(Pt 5):329-336.
22. Sugimoto M., Ohishi K., Ikawa Y. Role of cell-mediated immunity in bovine leukemia virus (BLV) infection in ruminants: its implication for the vaccination strategy against retroviruses. Ther Immunol 1994, 1:297-301.
23. Kabeya H., Ohashi K., Onuma M. Host immune responses in the course of bovine leukemia virus infection. J Vet Med Sci 2001, 63:703-708.
24. Florins A., Gillet N., Asquith B., Boxus M., Burteau C., Twizere J.C., et al. Cell dynamics and immune response to BLV infection: a unifying model. Front Biosci 2007, 12:1520-1531.
25. Usui T., Konnai S., Tajima S., Watarai S., Aida Y., Ohashi K., et al. Protective effects of vaccination with bovine leukemia virus (BLV) Tax DNA against BLV infection in sheep. J Vet Med Sci 2003, 65:1201-1205.
26. Babiuk S., Tsang C., van Drunen Littel-van den Hurk, Babiuk L.A., Griebel P.J. A single HBsAg DNA vaccination in combination with electroporation elicits long-term antibody responses in sheep. Bioelectrochemistry 2007, 70:269-274.
27. Willems L., Kettmann R., Dequiedt F., Portetelle D., Voneche V., Cornil I., et al. In vivo infection of sheep by bovine leukemia virus mutants. J Virol 1993, 67:4078-4085.
28. Mena A., Nichani A.K., Popowych Y., Ioannou X.P., Godson D.L., Mutwiri G.K., et al. Bovine and ovine blood mononuclear leukocytes differ markedly in innate immune responses induced by Class A and Class B CpG-oligodeoxynucleotide. Oligonucleotides 2003, 13:245-259.
29. Griebel P., Beskorwayne T., Godson D.L., Popowych Y., Hein W. Cloning non-transformed sheep B cells. J Immunol Methods 2000, 237:19-28.
30. Baum C., Hegewisch-Becker S., Eckert H.G., Stocking C., Ostertag W. Novel retroviral vectors for efficient expression of the multidrug resistance (mdr-1) gene in early hematopoietic cells. J Virol 1995, 69:7541-7547.
31. Van den Broeke A., Bagnis C., Ciesiolka M., Cleuter Y., Gelderblom H., Kerkhofs P., et al. In vivo rescue of a silent tax-deficient bovine leukemia virus from a tumor-derived ovine B-cell line by recombination with a retrovirally transduced wild-type tax gene. J Virol 1999, 73:1054-1065.
32. Oumouna M., Jaso-Friedmann L., Evans D.L. Flow cytometry-based assay for determination of teleost cytotoxic cell lysis of target cells. Cytometry 2001, 45:259-266.
33. Uwiera R.R., Rankin R., Adams G.P., Pontarollo R., van Drunen Littel-van den Hurk, Middleton D.M., et al. Effects of intradermally administered plasmid deoxyribonucleic acid on ovine popliteal lymph node morphology. Anat Rec 2001, 262:186-192.
34. Donnelly J.J., Ulmer J.B., Shiver J.W., Liu M.A. DNA vaccines. Annu Rev Immunol 1997, 15:617-648.
35. Wang R., Doolan D.L., Le T.P., Hedstrom R.C., Coonan K.M., Charoenvit Y., et al. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 1998, 282:476-480.
36. Moules V., Pomier C., Sibon D., Gabet A.S., Reichert M., Kerkhofs P., et al. Fate of premalignant clones during the asymptomatic phase preceding lymphoid malignancy. Cancer Res 2005, 65:1234-1243.
37. Pomier C., Alcaraz M.T., Debacq C., Lancon A., Kerkhofs P., Willems L., et al. Early and transient reverse transcription during primary deltaretroviral infection of sheep. Retrovirology 2008, 5:16.
38. Pomier C., Alcaraz M.T., Debacq C., Lancon A., Kerkhofs P., Willems L., et al. A dose-effect relationship for deltaretrovirus-dependent leukemogenesis in sheep. Retrovirology 2009, 6:30.
39. Gatei M.H., Naif H.M., Kumar S., Boyle D.B., Daniel R.C., Good M.F., et al. Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 T-cell response to gp51 peptide 51-70. J Virol 1993, 67:1803-1810.
40. Hislop A.D., Good M.F., Mateo L., Gardner J., Gatei M.H., Daniel R.C., et al. Vaccine-induced cytotoxic T lymphocytes protect against retroviral challenge. Nat Med 1998, 4:1193-1196.
41. Mateo L., Gardner J., Suhrbier A. Delayed emergence of bovine leukemia virus after vaccination with a protective cytotoxic T cell-based vaccine. AIDS Res Hum Retroviruses 2001, 17:1447-1453.
42. Nagai M., Usuku K., Matsumoto W., Kodama D., Takenouchi N., Moritoyo T., et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 1998, 4:586-593.
43. Taylor G.P., Hall S.E., Navarrete S., Michie C.A., Davis R., Witkover A.D., et al. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J Virol 1999, 73:10289-10295.